Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFQ056 proof-of-concept study in Huntington's disease chorea
2009-011743-39Phase 2Terminated
- Sponsor
- Novartis
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Huntington disease (HD) comparing AFQ056 with Placebo (2 arms). Primary endpoints: Change in chorea severity by UHDRS maximal chorea score and Orientation index from quantitative grip force motor assessment. Started Aug 2009; status: terminated.
02
Drugs
mavoglurant
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on 2009-011743-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011743-39.